Effectiveness of PHR-160 spray in recovery of hospitalized patients with Covid-19 in Isfahan province in 1399

Phase 3

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200411047029N1
• Lead Sponsor: The Research Institute of Food and Secrets TAAMASRAR

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 198

Inclusion Criteria

Age more than 18 years
Definite diagnosis of SARS-CoV-2 virus based on PCR
Diagnosis of pneumonia consistent with lung involvement with COVID-19 on CT scan
Need to be admitted to the ICU at the beginning of hospitalization

Exclusion Criteria

Having comorbidities (chronic kidney failure, cirrhosis, severe heart failure (less than 25% EF), active or untreated cancer)
Pregnancy and breastfeeding
Patients with hepatic enzymes including aspartate transaminase (AST) and alanine transaminase (ALT) at 5 times more than normal amount

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration and severity of symptoms (cough and shortness of breath). Timepoint: Daily. Method of measurement: Case file-Query from patients.;Duration of hospitalization. Timepoint: Daily. Method of measurement: Case file.;Blood oxygen levels. Timepoint: Daily. Method of measurement: Pulse Oximeters.;Requirement for ICU admission. Timepoint: Daily. Method of measurement: Doctor diagnosis.;Duration of hospitalization in the ICU. Timepoint: Daily. Method of measurement: Case file.;Death rate. Timepoint: Daily. Method of measurement: Case file.